Centre for Evolution and Cancer (CEC) (@cec-icr) Bsky

Adaptive Therapy Abstract. A number of successful systemic therapies are available for treatment of disseminated cancers. However, tumor response is often transient, and therapy frequently fails due to emergence of re...

Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper:
aacrjournals.org/cancerres/ar...

& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social

11 months ago 2 1 0 0

In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer.

We eagerly await the clinical trial results - they will be definitive.

11 months ago 3 1 2 0

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha... Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...

This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...

11 months ago 4 2 1 0

Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...

With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...

@icr.ac.uk @qmbci.bsky.social

11 months ago 36 6 2 0

Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.

1 year ago 12 5 1 0

Frequent evolution of BRCA2 reversion mutations during PARPi treatment in prostate cancer

1 year ago 2 0 0 0

Welcome to #bsky @alejandrapcelab.bsky.social ! Alejandra Bruna leads the paediatric cancer evolution (PCE) lab here in our @cec-icr.bsky.social. Focusing on dissecting the role of phenotypic plasticity in childhood cancer evolution and therapy response.

1 year ago 0 0 0 0

Posts by Centre for Evolution and Cancer (CEC)